280 related articles for article (PubMed ID: 29219621)
1. Clinical trial transparency update: an assessment of the disclosure of results of company-sponsored trials associated with new medicines approved in Europe in 2014.
Deane BR; Porkess S
Curr Med Res Opin; 2018 Jul; 34(7):1239-1243. PubMed ID: 29219621
[TBL] [Abstract][Full Text] [Related]
2. Clinical trial transparency update: an assessment of the disclosure of results of company-sponsored trials associated with new medicines approved in Europe in 2013.
Deane BR; Sivarajah J
Curr Med Res Opin; 2017 Mar; 33(3):473-478. PubMed ID: 27869482
[TBL] [Abstract][Full Text] [Related]
3. Clinical trial transparency update: an assessment of the disclosure of results of company-sponsored trials associated with new medicines approved in Europe in 2012.
Rawal B; Deane BR
Curr Med Res Opin; 2015; 31(7):1431-5. PubMed ID: 25942525
[TBL] [Abstract][Full Text] [Related]
4. Clinical trial transparency: an assessment of the disclosure of results of company-sponsored trials associated with new medicines approved recently in Europe.
Rawal B; Deane BR
Curr Med Res Opin; 2014 Mar; 30(3):395-405. PubMed ID: 24168052
[TBL] [Abstract][Full Text] [Related]
5. Delays in completion and results reporting of clinical trials under the Paediatric Regulation in the European Union: A cohort study.
Hwang TJ; Tomasi PA; Bourgeois FT
PLoS Med; 2018 Mar; 15(3):e1002520. PubMed ID: 29494592
[TBL] [Abstract][Full Text] [Related]
6. Clinical trial registration, reporting, publication and FDAAA compliance: a cross-sectional analysis and ranking of new drugs approved by the FDA in 2012.
Miller JE; Korn D; Ross JS
BMJ Open; 2015 Nov; 5(11):e009758. PubMed ID: 26563214
[TBL] [Abstract][Full Text] [Related]
7. Measuring clinical trial transparency: an empirical analysis of newly approved drugs and large pharmaceutical companies.
Miller JE; Wilenzick M; Ritcey N; Ross JS; Mello MM
BMJ Open; 2017 Dec; 7(12):e017917. PubMed ID: 29208616
[TBL] [Abstract][Full Text] [Related]
8. Adaptive designs in clinical trials: from scientific advice to marketing authorisation to the European Medicine Agency.
Collignon O; Koenig F; Koch A; Hemmings RJ; Pétavy F; Saint-Raymond A; Papaluca-Amati M; Posch M
Trials; 2018 Nov; 19(1):642. PubMed ID: 30454061
[TBL] [Abstract][Full Text] [Related]
9. Design characteristics, risk of bias, and reporting of randomised controlled trials supporting approvals of cancer drugs by European Medicines Agency, 2014-16: cross sectional analysis.
Naci H; Davis C; Savović J; Higgins JPT; Sterne JAC; Gyawali B; Romo-Sandoval X; Handley N; Booth CM
BMJ; 2019 Sep; 366():l5221. PubMed ID: 31533922
[TBL] [Abstract][Full Text] [Related]
10. Clinical trial design and dissemination: comprehensive analysis of clinicaltrials.gov and PubMed data since 2005.
Zwierzyna M; Davies M; Hingorani AD; Hunter J
BMJ; 2018 Jun; 361():k2130. PubMed ID: 29875212
[TBL] [Abstract][Full Text] [Related]
11. The characteristics and regulations of adaptive designs from 2008 to 2020: An overview of European Medicines Agency approvals.
Huang X; Ma J; Lu Z; Huang L
Int J Clin Pharmacol Ther; 2023 Oct; 61(10):445-454. PubMed ID: 37548455
[TBL] [Abstract][Full Text] [Related]
12. Sharing of clinical trial data and results reporting practices among large pharmaceutical companies: cross sectional descriptive study and pilot of a tool to improve company practices.
Miller J; Ross JS; Wilenzick M; Mello MM
BMJ; 2019 Jul; 366():l4217. PubMed ID: 31292127
[TBL] [Abstract][Full Text] [Related]
13. Clinical trial transparency: a reassessment of industry compliance with clinical trial registration and reporting requirements in the United States.
Lassman SM; Shopshear OM; Jazic I; Ulrich J; Francer J
BMJ Open; 2017 Sep; 7(9):e015110. PubMed ID: 28942418
[TBL] [Abstract][Full Text] [Related]
14. Cancer Therapy Approval Timings, Review Speed, and Publication of Pivotal Registration Trials in the US and Europe, 2010-2019.
Lythgoe MP; Desai A; Gyawali B; Savage P; Krell J; Warner JL; Khaki AR
JAMA Netw Open; 2022 Jun; 5(6):e2216183. PubMed ID: 35687337
[TBL] [Abstract][Full Text] [Related]
15. Transparent collaboration between industry and academia can serve unmet patient need and contribute to reproductive public health.
D'Hooghe T
Hum Reprod; 2017 Aug; 32(8):1549-1555. PubMed ID: 28854594
[TBL] [Abstract][Full Text] [Related]
16. Information on new drugs at market entry: retrospective analysis of health technology assessment reports versus regulatory reports, journal publications, and registry reports.
Köhler M; Haag S; Biester K; Brockhaus AC; McGauran N; Grouven U; Kölsch H; Seay U; Hörn H; Moritz G; Staeck K; Wieseler B
BMJ; 2015 Feb; 350():h796. PubMed ID: 25722024
[TBL] [Abstract][Full Text] [Related]
17. A Qualitative Study on the Differences Between Trial Populations and the Approved Therapeutic Indications of Antineoplastic Agents by 3 Regulatory Agencies From 2010 to 2018.
Sumi E; Asada R; Lu Y; Ito-Ihara T; Grimes KV
Clin Ther; 2020 Feb; 42(2):305-320.e0. PubMed ID: 32008723
[TBL] [Abstract][Full Text] [Related]
18. The evidence base for psychotropic drugs approved by the European Medicines Agency: a meta-assessment of all European Public Assessment Reports.
Erhel F; Scanff A; Naudet F
Epidemiol Psychiatr Sci; 2020 Apr; 29():e120. PubMed ID: 32336312
[TBL] [Abstract][Full Text] [Related]
19. Commitments by the biopharmaceutical industry to clinical trial transparency: the evolving environment.
Baronikova S; Purvis J; Southam E; Beeso J; Panayi A; Winchester C
BMJ Evid Based Med; 2019 Oct; 24(5):177-184. PubMed ID: 30898790
[TBL] [Abstract][Full Text] [Related]
20. Clinical study reports published by the European Medicines Agency 2016-2018: a cross-sectional analysis.
Byrne D; Prendergast C; Fahey T; Moriarty F
BMJ Open; 2023 May; 13(5):e068981. PubMed ID: 37188475
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
